Poland· PL-100205934

Liść Senesu

A medicinal product containing sennae foliolum, registered in Poland by Zakład Zielarski "Kawon-Hurt" Nowak Sp.J..

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedLiść SenesuATC—REGISTER NO.PL-100205934PACKS LISTED1CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Sennae foliolum
Manufacturer
Zakład Zielarski "Kawon-Hurt" Nowak Sp.J.
Country
Poland (PL)
ATC code
—
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909994370555

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/aa12b607-32ec-44dc-8d57-72dcae0c07bc
GET /v1/drugs/aa12b607-32ec-44dc-8d57-72dcae0c07bc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Zioła do zaparzania",
  "source": "urpl",
  "strength": "25-27,5 mg glikozydów hydroksyantracenowych w przeliczeniu na sennozyd B/1,0 g",
  "packaging": "05909994370555 ¦ OTC ¦ 22151\n1 torebka 50 g",
  "substance": "Sennae foliolum 25-27,5 mg glikozydów hydroksyantracenowych w przeliczeniu na sennozyd B/1,0 g",
  "common_name": "Sennae foliolum",
  "pl_product_id": "100205934",
  "pozwolenie_nr": "IL-3705/LN",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about sennae foliolum.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.